Skip to main content
. Author manuscript; available in PMC: 2017 Jun 15.
Published in final edited form as: J Immunol. 2016 May 4;196(12):5047–5055. doi: 10.4049/jimmunol.1600306

Figure 2. CSF1R is required for host defense in pneumonia.

Figure 2

Concentration of circulating monocytes (A) and lung mononuclear phagocytes (B) in uninfected mice after administration of daily CSF1R antibody or isotype control for 7 days using the gating strategy depicted in Figure 3A; n = 4–5 per group (* p < 0.05, Mann-Whitney). (C) Outcome of pneumonia in animals treated with anti-CSFR1 or isotype control Ab; n = 23–24 per group from 2 experiments (** p < 0.01, Log-rank test). (D) Bacterial burden in lungs of animals with pneumonia treated with anti-CSFR1 or isotype control Ab on day 3 of infection. Data from 2 experiments. Samples with no recoverable bacteria are depicted as 1 colony-forming unit. (* p < 0.05, Mann-Whitney).